Clinical trial
A Multicenter, Exploratory Clinical Study of Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia
NCT07933146 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Exploratory Clinical Study of Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- October 31, 2028
- Enrollment
- 96 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 2 arms.
-
Hetrombopag sequential group
-
Recombinant human thrombopoietin group
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Response rate
Proportion of participants achieving treatment response
Lead sponsor's other trials
The First Affiliated Hospital of Zhengzhou University, most recent start first.
+121 more trials
Similar trials
Same condition (Thrombocytopenia) and phase, most recent start first.
+114 more trials See the condition page